Sermonix Pharmaceuticals Inc is a privately held, Ohio-based biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s lead candidate is oral lasofoxifene. Lasofoxifene is currently under investigation in a phase II trial and is thought to be a potent third-generation selective estrogen receptor modulator (SERM) (also known as an estrogen agonist/antagonist) with high affinity for the estrogen receptor 1 (ESR1) receptor. Previous clinical development programs have suggested potential benefit to breast, bone, and vaginal tissue. Sermonix is currently focused on the study of lasofoxifene for advanced breast cancer treatment, particularly in patients with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2-) breast cancer who have developed an ESR1 mutation.
The company was founded in 2014 by David Portman, MD, a leading clinical researcher and expert in women’s health, sexual medicine and menopause, and SERM therapy.